title: Effects of the ethyl acetate fraction of Spatholobi caulis on tumour cell aggregation and migration.
abstract: The ethyl acetate (EA) fraction obtained from a methanol extract of Spatholobi caulis (Leguminosae) has been investigated for anti-metastatic activities in vitro. The EA fraction of Spatholobi caulis inhibited platelet aggregation induced by B16BL6 melanoma cells with an IC(50) of 50 microgram/mL. The EA fraction significantly inhibited HT1080 cancer cell invasion through a matrigel-coated filter with an IC(50) of 25 microgram/mL. Messenger RNA expression of uPA was effectively decreased in HT1080 cells by the EA fraction of Spatholobi caulis with an IC(50) of 30 microgram/mL, but the expressions of MMP-2 (matrix metalloproteinase) and TIMPs (tissue inhibitors of metalloproteinases) were not changed. These findings indicated that the EA fraction suppressed tumour cell invasion by downregulation of uPA (urokinase-type plasminogen activator). Taken together, these results suggest that the EA fraction of Spatholobi caulis may have anti-metastatic activities by blocking tumour cell-induced platelet aggregation (TCIPA) and tumour cell invasion.
authors.affiliation: Department of Oncology, Graduate School of East-West Medical Science, Kyunghee University, Yongin 449-701, Korea.
authors.forename: In-Cheol
authors.initials: IC
authors.lastname: Kang
authors.forename: Seung-Ae
authors.initials: SA
authors.lastname: Kim
authors.forename: Gyu Yong
authors.initials: GY
authors.lastname: Song
authors.forename: Nam-In
authors.initials: NI
authors.lastname: Baek
authors.forename: Young-Doo
authors.initials: YD
authors.lastname: Park
authors.forename: Shi Yong
authors.initials: SY
authors.lastname: Ryu
authors.forename: Ikuo
authors.initials: I
authors.lastname: Saiki
authors.forename: Sung-Hoon
authors.initials: SH
authors.lastname: Kim
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017931:DNA Primers; D004305:Dose-Response Relationship, Drug; D007887:Fabaceae; D005354:Fibrosarcoma / Q000188:drug therapy; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D008813:Mice, Inbred ICR; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018547:Plant Stems; D010974:Platelet Aggregation / Q000187:drug effects; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019714:Tissue Inhibitor of Metalloproteinases / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D017931:DNA Primers; D010936:Plant Extracts; D012333:RNA, Messenger; D019714:Tissue Inhibitor of Metalloproteinases; D020778:Matrix Metalloproteinase 2